New Risk • Feb 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: €9.29m (US$9.66m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£2.4m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€9.29m market cap, or US$9.66m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£207k net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£2.7m revenue, or US$3.4m). Reported Earnings • Feb 11
Full year 2024 earnings released: UK£0.047 loss per share (vs UK£0.085 loss in FY 2023) Full year 2024 results: UK£0.047 loss per share (improved from UK£0.085 loss in FY 2023). Revenue: UK£2.74m (up 138% from FY 2023). Net loss: UK£3.50m (loss narrowed 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. 공고 • Feb 03
Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025 Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2025. Location: 201 temple chambers, 3 7 temple avenue, ec4y 0dt, london United Kingdom 공고 • Jan 31
Oncimmune Holdings plc Provides Revenue Guidance for the First Half and for the Fiscal Year 2025 Oncimmune Holdings plc provided revenue guidance for the first half of fiscal year 2025. For the period, the company's revenue is likely to be approximately £1.4 million, an increase of circa 20% on the prior year (£1.19 million) and the Company continues to add to its broad pipeline of potential contracts.
For the year 2025, the company expects revenue to be in the region of £4 million, which would be an uplift of 33% vs FY2024 and growth of around 250% vs FY2023. The company expects to have much greater visibility on its revenue in the second half of the financial year. New Risk • Dec 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended February 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported February 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.9m market cap, or US$22.1m). New Risk • Nov 14
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 51% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.4m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€20.8m market cap, or US$21.9m). Breakeven Date Change • Oct 24
No longer forecast to breakeven The analyst covering Oncimmune Holdings no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of UK£552.0k in 2025. New forecast suggests the company will make a loss of UK£207.0k in 2025. New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (15% average weekly change). Minor Risk Market cap is less than US$100m (€17.0m market cap, or US$18.9m). 공고 • Aug 10
Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025 Oncimmune Holdings plc reaffirmed revenue guidance for the fiscal year 2024 and provided earnings guidance for the fiscal year 2025. The continued commercial traction, and expected acceleration due to the new commercial team fully bedding in, give Oncimmune's Board confidence in its revenue guidance for fiscal year 2024 of approximately £3 million (2023: £1.15 million from continuing operations).
On the back of continued revenue growth, the Board expects the Company to achieve profitability in fiscal year 2025. New Risk • Jun 10
New major risk - Negative shareholders equity The company has negative equity. Total equity: -UK£1.3m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.1m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-UK£1.3m). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£1.1m net loss next year). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (€14.0m market cap, or US$15.1m). 공고 • May 19
Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024 Oncimmune Holdings plc announced that they will report first half, 2024 results on May 21, 2024 Board Change • May 16
Less than half of directors are independent There are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. 4 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Member of Scientific Board Ola Winqvist is the most experienced director on the board, commencing their role in 2018. Independent Non-Executive Director John Goold was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Reported Earnings • Mar 01
Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022) Full year 2023 results: UK£0.085 loss per share (improved from UK£0.13 loss in FY 2022). Revenue: UK£1.15m (down 62% from FY 2022). Net loss: UK£6.15m (loss narrowed 33% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings. 공고 • Mar 01
Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024 Oncimmune Holdings plc provided earnings guidance for the year 2024. For the period, the company expects revenue to be approximately £3 million, compared with Fiscal Year 2023 revenue from continuing operations of £1.2 million, a growth rate of 150%. Coming up to the end of H1 Fiscal Year 2024, work to achieve approximately 75% of the forecast Fiscal Year 2024 revenue has been secured, with the majority of samples received or expected imminently allowing lab work to begin and revenue to be recognised in due course. 공고 • Feb 02
Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024 Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024, at 10:00 Coordinated Universal Time. Location: At the offices of Singer Capital Markets, 1 Bartholomew Lane London United Kingdom New Risk • Jan 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended August 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£4.2m). Revenue has declined by 14% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported August 2022 fiscal period end). Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (UK£3.0m revenue, or US$3.8m). Market cap is less than US$100m (€21.5m market cap, or US$23.3m). 공고 • Nov 30
Oncimmune Holdings plc Announces Board Changes Oncimmune Holdings plc announced on 12 October 2023, Dr. Annalisa Jenkins has decided to step down from the Board and a new Senior Independent Non-Executive Director, Sally Waterman, has been appointed. The transition of Annalisa's responsibilities has now been completed and she has therefore ceased to be a director with immediate effect. Board Change • Nov 02
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Non-Executive Director Annalisa Jenkins is the most experienced director on the board, commencing their role in 2018. Senior Independent Non-Executive Director Sally Waterman was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. 공고 • Oct 12
Oncimmune Holdings plc Announces Changes to the Board Oncimmune's new focus on its ImmunoINSIGHTS business, having disposed of its early cancer diagnostic business in May 2023, the composition of Oncimmune's board of directors (the "Board") is undergoing further change. Tim Bunting, who has been a director of Oncimmune since 2016, has stepped down from the Board with immediate effect. Tim was one of Oncimmune's earliest investors and continued to support it for over 15 years, many of them as a non-executive director. Tim remains a major shareholder of Oncimmune, having supported its latest fundraise in December 2022, and has given his full backing to the Company's new management team. Dr Annalisa Jenkins has also decided to step down from the Board by the end of 2023. Annalisa has been a director of Oncimmune since January 2018 and has served as the Company's Senior Independent Director and Chair of its Remuneration Committee. To replace Dr Annalisa Jenkins, Oncimmune announced the appointment of Sally Waterman. Sally has over 30 years of strategic and operational experience in the life science industry, including leading R&D and extensive involvement in M&A, and has worked for large pharma, small biotech/biopharma and contract service companies. Once all of the changes set out above are completed, and following the departure of Andrew Unitt as previously announced on 12 July 2023, the Board will consist of Alistair Macdonald (Non-executive Chair), Dr Sally Waterman (Senior Independent Non-executive Director and Chair of the Remuneration Committee), John Goold (Independent Non-executive Director and Chair of the Audit Committee) and Martin Gouldstone (Chief Executive Officer). 공고 • May 23
Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million. Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million on May 22, 2023. The consideration of £13 million is in cash, structured as consideration for equity and debt repayment, of which £1.3 million in cash is being held in escrow for 12 months in the event of any claim by Freenome against the customary warranties and indemnity given to Freenome in the sale and purchase agreement. Separately, Oncimmune Germany GmbH, Oncimmune Holdings' wholly-owned pharma services business trading as ImmunoINSIGHTS, and Freenome have also signed a long-term Master Services Agreement. Oncimmune Holdings has an existing debt facility with IPF Management SA with an outstanding principal balance of €11.6 million prior to this transaction. In connection with the transaction, Oncimmune has agreed to repay €7.2 million (being €5.6 million of principal and €1.6 million of interest) of the outstanding IPF Facility. The Board of Oncimmune Holdings considers that the repayment of debt under the IPF Facility, the repayment profile of the new IPF Facility, together with the net proceeds from the transaction, removes any material uncertainty as regards going concern. Phil Davies, Harry Gooden, George Tzimas and James Fischer of Nplus1 Singer Advisory LLP acted as the financial advisor to Oncimmune Holdings plc (AIM:ONC).Freenome Holdings, Inc. completed the acquisition of Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million on May 22, 2023. 공고 • Feb 04
Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023 Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023, at 10:00 Coordinated Universal Time. Location: offices of Pinsent,Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES London United Kingdom 공고 • Jan 13
Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director Oncimmune Holdings plc announced that further to the announcement made on 7 December 2022, John Goold has been appointed to the Board of the Company as Non-Executive Director with immediate effect, following the successful completion of customary due diligence checks by the Company's Nominated Adviser. Additional Information in respect of the AIM Rules: The following information regarding the appointment of John Howard Goold, aged 51, is disclosed under Schedule 2(g) of the AIM Rules for Companies. 공고 • Dec 15
Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million. Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,622,221
Price\Range: £0.45
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,044,446
Price\Range: £0.45 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Annalisa Jenkins was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 22
Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021) Full year 2022 results: UK£0.14 loss per share (further deteriorated from UK£0.072 loss in FY 2021). Revenue: UK£3.86m (up 3.7% from FY 2021). Net loss: UK£9.51m (loss widened 106% from FY 2021). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Buying Opportunity • Aug 01
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 29%. The fair value is estimated to be €1.19, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 92% over the last 3 years. Earnings per share has grown by 17%. 공고 • Jul 08
Oncimmune Holdings plc Announces Board Changes Oncimmune Holdings plc announced the appointment of Alistair Macdonald as Non-executive Chair, effective immediately. Alistair succeeds Meinhard Schmidt as Chair of the Board, who has retired from the Board. Alistair brings a wealth of knowledge in the pharma services sector, developed through his 25-year career in life sciences, culminating in his role as CEO of leading, integrated CRO Syneos Health Inc. (Nasdaq: SYNH; market cap c.$6.6 billion) ("Syneos"), which he held for 6 years, before which he was CEO of INC Research which merged with inVentiv Health to become Syneos in 2017. During his time with INC and then Syneos, revenue grew from $20m to over $5.0 billion. Prior to becoming a CEO, Alistairled multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services. Over the last 25 years, he has held management positions in the pharmaceutical industry across manufacturing, consultancy, business and corporate development, data management and clinical operations. Alistair retired as CEO of Syneos Health in April 2022, a company that he led post-merger through further substantial organic as well as inorganic growth. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Until recently, Alistair has also served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). Senior Independent Non-Executive Director Annalisa Jenkins was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Mar 02
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: UK£0.07 loss per share (down from UK£0.041 loss in 1H 2021). Revenue: UK£1.43m (down 22% from 1H 2021). Net loss: UK£4.86m (loss widened 87% from 1H 2021). Revenue missed analyst estimates by 34%. Over the next year, revenue is forecast to grow 316%, compared to a 64% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. 공고 • Feb 18
Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain Oncimmune Holdings plc announced that the Regional Ministry of Health for Aragon, Spain has announced that the Company's Early CDT Lung blood test is to be adopted by the Thoracic Surgery Unit of the University Hospital Miguel Servet, Zaragoza, for use on solitary pulmonary nodules. This approval follows the issuing of a favourable assessment and report by the Evaluation Committee of the Aragonese Health System having met the necessary criteria with regards to efficacy and safety. The issuing of this positive assessment by the Aragon Public Health Service and the subsequent approval is considered an important development by Oncimmune and its Spanish distributor, Sabartech, towards the adoption of the blood test by other regional public health systems in Spain. This latest approval in Spain follows an earlier announcement on 2 November 2021 that EarlyCDT Lung had been authorised for use within the Spanish Public Health Service by the Galician Health Service (SERGAS), the first public health service in Spain to use the EarlyCDT Lung test. Reported Earnings • Nov 04
Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: UK£3.72m (up UK£3.21m from FY 2020). Net loss: UK£4.63m (loss narrowed 45% from FY 2020). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. 공고 • Jul 24
Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles Oncimmune Holdings plc announced the pre-publication of the first results from its collaboration with Cedars-Sinai Medical Center in Los Angeles, entitled: "Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection"1. The paper focuses on the characterisation of sex-specific prevalence and selectivity of autoantibody responses to the SARS-CoV-2 virus. Since the beginning of the COVID-19 pandemic, there has been an unprecedented number of initiatives from the life sciences industry and research institutions to understand and respond to the effects of COVID-19, but despite first generation vaccines now being deployed to fight the disease, the need to expand understanding of the immune response to SARS-CoV-2 still exists. The results of this study demonstrate the potential of the SeroTagTM Infectious Diseases discovery array to enable a better understanding of how SARS-CoV-2 stimulates the immune reaction and predicts responses to vaccines and therapeutics against the virus. The aim of this initial research project was to use the SeroTag Infectious Diseases discovery array to detect autoantibodies to over 90 antigens previously linked to a range of classic autoimmune diseases. The researchers sought to comprehensively examine the diversity of autoantibody responses in male and female health care workers who were exposed to SARS-CoV-2 and were asymptomatic, or experienced minor symptoms. 공고 • May 21
Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology Oncopeptides AB (publ) announces that three abstracts with data on melflufen (INN melphalan flufenamide) in relapsed refractory multiple myeloma, RRMM, have been accepted by the 2021 American Society of Clinical Oncology, ASCO, and have now been published online. The clinical data presentations include updates on Oncopeptides' ANCHOR and LIGHTHOUSE studies as well as a pooled analysis of the O-12-M1 and HORIZON studies in patients who have been exposed to or become refractory to prior alkylators. Below is a brief description of the abstracts that have been accepted by the ASCO. They will be available online at https://www.asco.org, on May 19th at 23:00 (CET). 1. ANCHOR (OP-104): MELFLUFEN PLUS DEXAMETHASONE AND BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS The ANCHOR study determined that the optimal dose of melflufen is 30 mg plus dexamethasone and bortezomib and the results showed clinical activity in heavily pretreated RRMM patients. Recruitment for this study is ongoing and updated data including efficacy and safety will be presented at ASCO. 2. LIGHTHOUSE (OP-108): A PHASE 3 STUDY OF MELFLUFEN IN COMBINATION WITH DEXAMETHASONE AND DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS The phase 3 LIGHTHOUSE study is a randomized, controlled, open-label study of melflufen plus dexamethasone in combination with daratumumab vs daratumumab alone in patients with RRMM previously treated with an immunomodulatory agent and a proteasome inhibitor, similar to the indication for daratumumab monotherapy. The primary objective is superiority of PFS. Key secondary endpoints include ORR (= PR), DOR, and safety. Patient recruitment is ongoing with a planned enrolment of 240 patients. 3. A POOLED ANALYSIS OF THE O-12-M1 AND HORIZON STUDIES: MELFLUFEN PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS (RRMM) WHO ARE EXPOSED OR REFRACTORY TO PRIOR ALKYLATORS This pooled analysis of the O-12-M1 and HORIZON studies showed that melflufen in combination with dexamethasone showed meaningful efficacy and demonstrated a clinically manageable safety profile in patients with RRMM who had been exposed or become refractory to prior alkylators. PEPAXTO® (melphalan flufenamide, also known as melflufen), in combination with dexamethasone, was granted accelerated approval by the FDA on February 26, 2021, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. 공고 • May 13
Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting Oncopeptides AB (publ) announces that new clinical and preclinical data have been accepted by the European Hematology Association, EHA, and been published online. The clinical data presentation contains interim results from the phase 2 BRIDGE study supporting the use of melflufen in relapsed refractory multiple myeloma patients with moderately impaired renal function. Two preclinical data presentations show the future potential of melflufen in treatments of other hematological diseases outside multiple myeloma. In addition, the last preclinical data presentation provides an increased understanding of melflufen 's mode of action. 1. Bridge (Op-107): A Phase 2 Pharmacokinetic Study Of Melflufen Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma And Impaired Renal Function: The study demonstrates that for patients receiving melflufen in the phase 2 BRIDGE study, the exposure to melphalan increased with reduced eGFR (Estimated Glomerular Filtration Rate), similar to what is observed during treatment with melphalan. The overall toxicity profile was as expected for melflufen and dexamethasone and no new safety signals were observed, supporting the use of melflufen in patients with moderate renal impairment. 2. Melflufen Demonstrates High Efficacy In Cytarabine And Venetoclax Resistant Aml Models: The study shows that multiple aminopeptidases are highly expressed in AML-samples, providing a good rationale for using melflufen therapy. Patients with Acute Myeloid Leukemia, often develop resistance to current treatments, including cytarabine and venetoclax, yet in pre-clinical models of resistance to these agents, melflufen shows high efficacy. 3. Melphalan Flufenamide Is A Highly Potent Anti-Neoplastic Agent In High Risk Dlbcl Models: Several aminopeptidase genes are highly expressed in samples of patients with DLBCL, Diffuse Large B-Cell Lymphoma, and their elevated expression is associated with significantly shorter survival. In preclinical in vitro tests of DLBCL cell lines, melflufen shows superior cytotoxicity compared to Standard of Care drugs doxorubicin and bendamustine. 4. Melflufen Rapidly Accumulates Within Tumor Cells And Distributes An Alkylating Payload To The Nucleus And Mitochondria: The increased lipophilicity of melflufen can affect the redistribution of the alkylating payload within the cell. Data show that melflufen, but not melphalan, localized significantly within lysosomes, endoplasmic reticulum and importantly mitochondria, which may affect the mechanism of cancer cell killing. Reported Earnings • Feb 18
First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020) The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: UK£1.83m (up 493% from 1H 2020). Net loss: UK£2.60m (loss narrowed 51% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 13
New 90-day high: €2.12 The company is up 15% from its price of €1.85 on 13 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 12% over the same period. 공고 • Jan 25
Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021 Oncimmune Holdings plc announced that they will report first half, 2021 results on Feb 15, 2021 공고 • Jan 22
Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021 Oncimmune Holdings plc announced that Dr Cheung To ("CT") has stepped down as a non-executive Director of the Company, effective from 19 January 2021. Dr To remains a Director of Genostics Company Limited ("Genostics"), part of the Gene Group Holdings Limited ("GGH") group, and stepping down is expected to enable Dr To focus on the continued development of GGH as it prepares for its future corporate and commercial activities. Genostics remains a significant shareholder of Oncimmune and its recent disposal of shares in Oncimmune, bringing its holding to below 10%, was undertaken in line with GGH's preparation for its anticipated corporate activities. Genostics remains Oncimmune's exclusive partner in China and continues to work closely with Oncimmune to gain market entry. Is New 90 Day High Low • Dec 16
New 90-day high: €2.04 The company is up 32% from its price of €1.55 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 공고 • Dec 15
Oncimmune Holdings plc Signs Commercial Contracts Oncimmune Holdings plc announced that it has signed a commercial contract to supply its EarlyCDT Lung blood test to NHS Norfolk & Waveney Clinical Commissioning Group. Additionally, the Company has also signed a commercial contract to supply EarlyCDT Lung blood test into the NHS Lung Health Check Programmes in Wessex and Yorkshire as part of the iDx-LUNG evaluation programme. Following in-depth due diligence by the NHS, the Company has also been notified that The National Institute for Health and Care Excellence (NICE) has selected the EarlyCDT Lung blood test for Diagnostics Assessment Guidance. This decision follows the publication by NICE in March 2020 of the positive Medtech Innovation Briefing 209 on 'EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules'. The successful completion of this assessment will further support wider market adoption of EarlyCDT Lung in the NHS. Is New 90 Day High Low • Nov 25
New 90-day high: €1.99 The company is up 32% from its price of €1.51 on 27 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 공고 • Nov 10
Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020 Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020, at 10:00 Coordinated Universal Time. Location: offices of Zeus Capital, 10 Old Burlington Street London United Kingdom Reported Earnings • Oct 30
Full year earnings released - €0.13 loss per share Over the last 12 months the company has reported total losses of UK£8.46m, with losses widening by 5.4% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 30
Annual earnings released: Revenue misses expectations Annual revenue missed analyst estimates by 54% at UK£509.0k. Revenue is forecast to grow 1,072% over the next year, compared to a 273% growth forecast for the Biotechs industry in Germany. 공고 • Oct 19
Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020 Oncimmune Holdings plc announced that they will report fiscal year 2020 results on Oct 30, 2020 공고 • Oct 04
Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma Oncopeptides AB (publ) announced that the open-label Expanded Access Program, sEAPort, for eligible U.S. patients, is formally open. Melflufen (INN melphalan flufenamide), is currently being evaluated in several clinical studies as a treatment for patients with triple-class refractory multiple myeloma. The sEAPort program is available to adults, age 18 and older, who have received at least two prior lines of therapy and whose multiple myeloma is refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody, (i.e., triple-class refractory multiple myeloma patients). The Expanded Access Program was initiated following the Company's June 30 submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with triple-class refractory multiple myeloma. The NDA and the sEAPort program are primarily supported by data from the pivotal phase 2 HORIZON study, which demonstrates that melflufen in combination with dexamethasone, has a potential to provide a therapeutic option for patients with relapsed refractory multiple myeloma who are hard to treat and have a poor prognosis, including patients with triple-class refractory multiple myeloma and patients with extramedullary disease. EAPs are designed to provide patients living with serious or life-threatening conditions access to investigational medicines when no comparable or satisfactory treatment options are available, alternative therapies have been exhausted or the patient is ineligible for ongoing interventional trials. 공고 • Sep 26
Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors Oncimmune Holdings plc announced that it has received £5.25 million in funding led by new investor, Balderton Capital (UK) LLP in 2007. As a part of the transaction, Tim Bunting joined the company’s board of directors. 공고 • Sep 24
Oncimmune Holdings plc Signs Collaboration with Genentech Oncimmune Holdings plc announced that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including Systemic Lupus Erythematosus (SLE). In this new project, Oncimmune will use its proprietary NavigAID panel to characterise autoantibody profiles from trial participants. Following completion of this project, Genentech has the option to expand the contract to profile additional samples. SLE is a chronic, incurable autoimmune disease associated with multiple symptoms that can flare up over time. Diagnosis of SLE can be challenging. An objective of the project includes better characterisation of the disease, where there is a high unmet need for an effective therapy. This project builds upon Oncimmune's broadening commercial footprint to not only deliver diagnostic tests, through EarlyCDT Lung and Liver, but also to partner with large pharmaceutical companies by profiling autoantibodies and developing commercial companion diagnostic tests through Oncimmune's ImmunoINSIGHTS service business. 공고 • Jun 18
An unknown buyer acquired an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham. An unknown buyer acquired an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham on June 15, 2020. The transaction is valued for approximately £1.5 million.
An unknown buyer completed the acquisition of an unknown stake in Oncimmune Holdings plc (AIM:ONC) from University of Nottingham on June 15, 2020. 
